| pubmed-article:9248749 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0015967 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0042029 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0007554 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0017436 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C0332282 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C1511237 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C1705509 | lld:lifeskim |
| pubmed-article:9248749 | lifeskim:mentions | umls-concept:C1550436 | lld:lifeskim |
| pubmed-article:9248749 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9248749 | pubmed:dateCreated | 1997-9-11 | lld:pubmed |
| pubmed-article:9248749 | pubmed:abstractText | The efficacy and safety of two different regimens for parenteral treatment of presumed severe febrile urinary tract infection were compared in a randomized study. One hundred fifty-eight patients were treated with either cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally or one bolus dose of gentamicin 3 mg/kg i.v. and norfloxacin from the start. Three patients randomized to cefotaxime died. Of the 101 patients with verified urinary tract infection, clinical response to assigned therapy was seen in 79% and 74%, respectively. There was no difference in fever duration between the two regimens. The results indicate that one bolus dose of gentamicin with early oral therapy is a safe and effective alternative to common parenteral regimens for empirical treatment of febrile urinary tract infection. | lld:pubmed |
| pubmed-article:9248749 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9248749 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9248749 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9248749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9248749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9248749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9248749 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9248749 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9248749 | pubmed:issn | 0934-9723 | lld:pubmed |
| pubmed-article:9248749 | pubmed:author | pubmed-author:ArnebornPP | lld:pubmed |
| pubmed-article:9248749 | pubmed:author | pubmed-author:SjöbergLL | lld:pubmed |
| pubmed-article:9248749 | pubmed:author | pubmed-author:VikerforsTT | lld:pubmed |
| pubmed-article:9248749 | pubmed:author | pubmed-author:SundmanKK | lld:pubmed |
| pubmed-article:9248749 | pubmed:author | pubmed-author:BladLL | lld:pubmed |
| pubmed-article:9248749 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9248749 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:9248749 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9248749 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9248749 | pubmed:pagination | 455-8 | lld:pubmed |
| pubmed-article:9248749 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:meshHeading | pubmed-meshheading:9248749-... | lld:pubmed |
| pubmed-article:9248749 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9248749 | pubmed:articleTitle | One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection. | lld:pubmed |
| pubmed-article:9248749 | pubmed:affiliation | Department of Infectious Diseases, Orebro Medical Center Hospital, Sweden. | lld:pubmed |
| pubmed-article:9248749 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9248749 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9248749 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9248749 | lld:pubmed |
